Technology Platform: Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC)
Trial Phase: Pre-clinical Study
Chronic Obstructive Pulmonary Disease (COPD) refers to a group of diseases that block airflow to the lungs and make it difficult to breathe. The two most common conditions that make up COPD are chronic bronchitis and emphysema, which gradually destroys the smallest air passages (bronchioles) in the lungs.
Currently the common treatments for COPD, such as use of steroids, inhalers and bronchodilator drugs, aim to control the symptoms and minimize further damage, but do not reverse the tissue damage. The major risk factors for COPD in China are tobacco smoking, biomass fuel use and genetic susceptibility.
Our pre-clinical study is being conducted by Shanghai First People’s Hospital, a leading teaching hospital affiliated with Shanghai Jiaotong University. Professor Zhou Xin, director of the hospital’s respiratory department and chairperson of Respiratory Diseases Division of Shanghai Medical Association, will lead the study as Principal Investigator.
Respiratory diseases account for 15% of deaths in China (Respirology 2013, Asian Pacific Society of Respirology). China currently has over 32 million patients suffering from COPD (Based on estimates by World Health Organization (WHO) of 2.5% prevalence of COPD in China)